Market Cap 68.76M
Revenue (ttm) 0.00
Net Income (ttm) -138.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,035,000
Avg Vol 2,823,808
Day's Range N/A - N/A
Shares Out 37.57M
Stochastic %K 45%
Beta -0.13
Analysts Strong Sell
Price Target $11.29

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
1599 Industrial Road, San Carlos, United States
raulsan79trader
raulsan79trader Jul. 27 at 8:17 AM
Biomea Fusion ($BMEA) just added Julianne Averill to its Board — a major strategic signal. Averill, former CFO at Chinook Therapeutics (acquired by Novartis for $3.5B), brings deep experience in oncology biotech deal-making, capital markets, and M&A. - Her background at Kura Oncology and Chinook gives her: Direct BD network with big pharma (Novartis, Pfizer, AZ) Proven ability to structure creative co-dev or licensing deals Insight into prepping clinical assets (like BMF-219) for acquisition With Biomea’s oncology pipeline advancing and funding needs growing, her arrival could accelerate strategic partnerships — or even set the stage for a future buyout. - Watch Q2 earnings for signals of deal discussions.
0 · Reply
GODOFUSD
GODOFUSD Jul. 25 at 7:13 PM
$BMEA https://x.com/GodOfUSD/status/1948405733973696760
1 · Reply
mrd4
mrd4 Jul. 25 at 6:40 PM
$BMEA A bit of an addition to the board per yesterday’s PR. Surprising that it’s not going up.
0 · Reply
Rob88ynn
Rob88ynn Jul. 25 at 4:42 PM
$BMEA they have to put out something to save this.
0 · Reply
hashbridges
hashbridges Jul. 25 at 4:33 PM
$BMEA approaching previous support on last low volume shorting attack (what we’ve had over the past few days). Expect a bounce between here and 1.65 back to 1.9-2. Real move comes with any news since this is basically a buyers strike right now allowing tiny shorts to move price thus much on a % basis
1 · Reply
BobBijawklah
BobBijawklah Jul. 25 at 2:11 PM
$BMEA Great summary on the t1d. So we saw a few very good responders in t1d. but there again t1d attacks beta cells through an immune system attack . So i think they hinted at the possibity of combining with an immune supressant. Honestly we all know this is an extremely risky and volatile investment however if they can pull of the t1d and get that to market when that happens 20 plus is easy risk a little to gain a lot. Also if the data is bad and they singal adding the immune therapy when it drops great oppurtunity to add. SIDD is stellar the only problem with that is how to get physicians and standards to test and isolate that group out of the larger t2d group.And you have the GLP1 that could be a target for large pharma to buy them straight out.
0 · Reply
nf04
nf04 Jul. 24 at 4:31 PM
$BMEA I think the T1D 26 weeks data might come in as a positive surprise. There are T1D studies showing a temporary rise in c peptide upon transiently augmented beta cell secretion, so BMF-219 should have a similar effect. For a long-term sustained effect it will surely have to be combined with an immunotherapy such as teplizumab (mAb) or baricitinib (JAKi). And a sustained effect in T2D after 52 weeks would surely be a strong readout demonstrating the long-term potential of the therapy.
1 · Reply
BobBijawklah
BobBijawklah Jul. 24 at 4:51 AM
$BMEA bmea has a lot of potential long term. Great assets. But I am getting a feeling like the t1d isn't good enough to move forward and the type two 52 week data isn't going to be be anything new. A lot of uncertainty. Potential yea they have it but I'll hold the lottery ticket for t1 and if that is a good readout back to double digit
1 · Reply
raulsan79trader
raulsan79trader Jul. 23 at 4:52 PM
$BMEA 👀
0 · Reply
hashbridges
hashbridges Jul. 23 at 4:38 PM
$BMEA all this talk of short squeezes and Meme stuff and over here we have a totally complacent set of shorters holding a stock down to 1/10th its analyst price target. Seems pretty obvious $GPRO $DNUT
1 · Reply
Latest News on BMEA
Biomea Fusion Announces Pricing of Public Offering of Securities

Jun 17, 2025, 11:15 PM EDT - 5 weeks ago

Biomea Fusion Announces Pricing of Public Offering of Securities


Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Jun 17, 2025, 7:28 PM EDT - 5 weeks ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR


Biomea Fusion Announces Proposed Public Offering of Securities

Jun 17, 2025, 4:33 PM EDT - 5 weeks ago

Biomea Fusion Announces Proposed Public Offering of Securities


Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 4 months ago

Biomea Fusion Announces Leadership Transition


raulsan79trader
raulsan79trader Jul. 27 at 8:17 AM
Biomea Fusion ($BMEA) just added Julianne Averill to its Board — a major strategic signal. Averill, former CFO at Chinook Therapeutics (acquired by Novartis for $3.5B), brings deep experience in oncology biotech deal-making, capital markets, and M&A. - Her background at Kura Oncology and Chinook gives her: Direct BD network with big pharma (Novartis, Pfizer, AZ) Proven ability to structure creative co-dev or licensing deals Insight into prepping clinical assets (like BMF-219) for acquisition With Biomea’s oncology pipeline advancing and funding needs growing, her arrival could accelerate strategic partnerships — or even set the stage for a future buyout. - Watch Q2 earnings for signals of deal discussions.
0 · Reply
GODOFUSD
GODOFUSD Jul. 25 at 7:13 PM
$BMEA https://x.com/GodOfUSD/status/1948405733973696760
1 · Reply
mrd4
mrd4 Jul. 25 at 6:40 PM
$BMEA A bit of an addition to the board per yesterday’s PR. Surprising that it’s not going up.
0 · Reply
Rob88ynn
Rob88ynn Jul. 25 at 4:42 PM
$BMEA they have to put out something to save this.
0 · Reply
hashbridges
hashbridges Jul. 25 at 4:33 PM
$BMEA approaching previous support on last low volume shorting attack (what we’ve had over the past few days). Expect a bounce between here and 1.65 back to 1.9-2. Real move comes with any news since this is basically a buyers strike right now allowing tiny shorts to move price thus much on a % basis
1 · Reply
BobBijawklah
BobBijawklah Jul. 25 at 2:11 PM
$BMEA Great summary on the t1d. So we saw a few very good responders in t1d. but there again t1d attacks beta cells through an immune system attack . So i think they hinted at the possibity of combining with an immune supressant. Honestly we all know this is an extremely risky and volatile investment however if they can pull of the t1d and get that to market when that happens 20 plus is easy risk a little to gain a lot. Also if the data is bad and they singal adding the immune therapy when it drops great oppurtunity to add. SIDD is stellar the only problem with that is how to get physicians and standards to test and isolate that group out of the larger t2d group.And you have the GLP1 that could be a target for large pharma to buy them straight out.
0 · Reply
nf04
nf04 Jul. 24 at 4:31 PM
$BMEA I think the T1D 26 weeks data might come in as a positive surprise. There are T1D studies showing a temporary rise in c peptide upon transiently augmented beta cell secretion, so BMF-219 should have a similar effect. For a long-term sustained effect it will surely have to be combined with an immunotherapy such as teplizumab (mAb) or baricitinib (JAKi). And a sustained effect in T2D after 52 weeks would surely be a strong readout demonstrating the long-term potential of the therapy.
1 · Reply
BobBijawklah
BobBijawklah Jul. 24 at 4:51 AM
$BMEA bmea has a lot of potential long term. Great assets. But I am getting a feeling like the t1d isn't good enough to move forward and the type two 52 week data isn't going to be be anything new. A lot of uncertainty. Potential yea they have it but I'll hold the lottery ticket for t1 and if that is a good readout back to double digit
1 · Reply
raulsan79trader
raulsan79trader Jul. 23 at 4:52 PM
$BMEA 👀
0 · Reply
hashbridges
hashbridges Jul. 23 at 4:38 PM
$BMEA all this talk of short squeezes and Meme stuff and over here we have a totally complacent set of shorters holding a stock down to 1/10th its analyst price target. Seems pretty obvious $GPRO $DNUT
1 · Reply
GODOFUSD
GODOFUSD Jul. 23 at 2:18 PM
0 · Reply
Rob88ynn
Rob88ynn Jul. 23 at 2:10 PM
$BMEA better volume to start off today
0 · Reply
Nomadess
Nomadess Jul. 23 at 4:13 AM
$BMEA speculative purchase for UTMAs x4, have others to balance it out, gotta take a risk on occasion. They don’t know when I lose 😆
0 · Reply
Mike93
Mike93 Jul. 22 at 6:13 PM
$BMEA sick of this stock 🤮 cost of opportunity in this market
2 · Reply
Patoun
Patoun Jul. 22 at 12:58 PM
$BMEA To be honnest I don't care about analyst's reccomandations. That do not mean anything . Look for example at W.C. Wainwright. Last year they had a price target of $128. They even had created a video on youtube featuring a diabete expert professor, about the potential of BIOMEA. I suspect them at that time having interests in that type of advertisements ... Then a few months later, the price target dropped to $40... And most recently to $4 !!! How on earth could we consider W.C. Wainwright as serious experts ? I cannot, even with lots of efforts and comedy talents 😜 If/when biomea shows that their technologies are efficient, without risks, then it'll become a real gem, a 3 digits price potential. In the meantime, I do not invest much on it. Cannot afford the risk. Just the money I would put in restaurants/ cinema per month.
1 · Reply
JarvisFlow
JarvisFlow Jul. 21 at 5:27 PM
D. Boral Capital has updated their rating for Biomea Fusion ( $BMEA ) to Buy with a price target of 16.
0 · Reply
GODOFUSD
GODOFUSD Jul. 21 at 5:12 PM
$BMEA boring as f, but loading more shares here. Don't know if 1.8 will hold, but it's the level i want to see turning support!
0 · Reply
hashbridges
hashbridges Jul. 21 at 3:56 PM
$BMEA and right on cue, low volume shorting to exaggerate pricing pressure.
0 · Reply
hashbridges
hashbridges Jul. 21 at 3:24 PM
$BMEA feels like the calm before the storm and based on price, the storm isn't going down but violently up. Taking some of my ridiculous gains on ETHT calls and rolling some into $3 10/25 calls...
0 · Reply
raulsan79trader
raulsan79trader Jul. 18 at 7:37 AM
$BMEA Buy before August, in gains you'll trust :D
1 · Reply
nf04
nf04 Jul. 18 at 2:57 AM
$BMEA the underwriter option expires tomorrow, I think a close just below 2 would be in line with the larger playbook, the following weeks should have a lot of technical upside, probably some catalysts ahead as well.
1 · Reply
lazzer
lazzer Jul. 17 at 3:46 PM
$POET Its trying $BMEA Going good $EOSE Also not to bad Im doing better than yesterday LOL
0 · Reply